Since the late 1990s, immunohistochemical (IHC) screening of breast cancer patients for HER2 has been the standard practice due to the introduction of HER2-targeted therapies such as trastuzumab [5,6,7]. The gene discussed is ERBB2; the disease is breast cancer.